The UF Health Cancer Center will be presenting at the American Society of Hematology (ASH) Annual Meeting in New Orleans, Louisiana, on Dec. 10-13, 2022.
The ASH Annual Meeting is the most comprehensive hematology event of the year. The meeting will provide an invaluable educational experience and overview of the latest scientific highlights in hematology. ASH is a great opportunity for hematology/oncology researchers to engage with colleagues and network with more than 25,000 hematology professionals from every subspecialty.
The full conference program is available here.
Oral Presentations
Saturday, Dec. 10
45. XPO1 Overexpression Is a Mechanism of Resistance to Eprenetapopt and 5-Azacitidine Therapy That Can be Therapeutically Exploited for the Treatment of TP53 Mutated Myeloid Malignancies
Author include Meghan Ferrall-Fairbanks, Ph.D.
10 a.m.
Career Development Lunch
Panelists include Olga A Guryanova, M.D., Ph.D., and Anita Rajasekhar, M.D.
11:15 a.m.-12:15 p.m.
617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Genomic Lesions and Therapeutic Implications
Moderators include Jatinder K. Lamba, Ph.D.
2-3:30 p.m.
240. Preliminary Data from the Phase I/II Study of TP-3654, a Selective Oral PIM1 Kinase Inhibitor, in Patients with Myelofibrosis Previously Treated with or Ineligible for JAK Inhibitor Therapy
Authors include Randy A. Brown, M.D.
3:15 p.m.
602. Myeloid Oncogenesis: Basic: Chromatin Organization and Metabolism
Moderators include Olga A Guryanova, M.D., Ph.D.
4-5:30 p.m.
296. NPM1 Mutation Reprograms Leukemic Transcription Network Via Reshaping CTCF-Defined TAD Topology
Authors include: Olga A Guryanova, M.D., Ph.D.
4:15 p.m.
101. Red Cells and Erythropoiesis, Excluding Iron I
Moderators include Jorg Bungert, Ph.D.
4-5:30 p.m.
Sunday, Dec. 11
415. Phosphorylation Stabilized TET1 Acts As an Oncoprotein and Therapeutic Target in B-Cell Acute Lymphoblastic Leukemia
Authors include Zhijian Qian, Ph.D.
9:30 a.m.
432. Personalization of Induction Therapy for Pediatric AML to Ara-C+Dauno+ Etoposide (ADE) or Clofarabine+Ara-C According to a Polygenic Ara-C SNP Score- ACS10
Presenter: Jatinder K. Lamba, Ph.D.
10:45 a.m.
Systems-Based Hematology Education and Networking Session
Chair: Marc Zumberg, M.D.
4:30-6:30 p.m.
Introduction to Systems-Based Hematology
Presenter: Marc Zumberg, M.D.
669. Evaluating the Impact of a Year-Long External Mentorship Pilot Program in Classical Hematology
Authors include Martina C. Murphy, M.D.
5 p.m.
Monday, Dec. 12
697 Endothelial mTOR Preserves Hematopoietic Stem Cell Fitness By Suppressing Thrombospondin1
Presenter: Pradeep Ramalingam, M.D., Ph.D.; Authors include Jason Butler, Ph.D.
10:30 a.m.
783 Long-Term Durable FVIII Expression with Improvements in Bleeding Rates Following AAV-Mediated FVIII Gene Transfer for Hemophilia A: Multiyear Follow-up on the Phase I/II Trial of SPK-8011
Authors include Tung Wynn, M.D.
11 a.m.
ASH Choosing Wisely® Campaign: 2022 ASH Choosing Wisely Champions
Chair: Marc Zumberg, M.D.
12:15-1:15 p.m.
Reducing Unnecessary Pre-Medication Prior to Parenteral Iron Therapy
Presenter: Carol M. Mathew, M.D.
12:15-1:15 p.m.
901 The Impact of Cumulative Anesthesia Exposure on Neurocognitive Outcomes in Children with High-Risk Precursor B Acute Lymphoblastic Leukemia: A Multicenter Children’s Oncology Group Study
Authors include John Kairalla, Ph.D.
2:45 p.m.
824 The Long Non-Coding RNA MALAT1 Is Necessary for Hematopoietic Stem and Progenitor Cell Expansion and Preleukemic Myeloproliferation in TET2 Deficient Myeloid Neoplasms
Authors include Meghan Ferrall-Fairbanks, Ph.D.
3 p.m.
986 Outcomes of Non-Myeloablative HLA-Haploidentical Bone Marrow Transplant with Thiotepa and Post-Transplant Cyclophosphamide in Children and Adults with Sickle Cell Disease, a Phase II Trial: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC2)
Authors include Biljana Horn, M.D.
4:45 p.m.
Poster Presentations
Saturday, Dec. 10
1493 A Cibersortx Signature Predicts Outcome in Pediatric AML Patients
Presenter: Francisco Marchi, B.S.; Authors include Jatinder K. Lamba, Ph.D.
5:30-7:30 p.m.
1412 A Pilot Study of Azacitidine As Epigenetic Priming for Chemotherapy in Infants Less Than 1 Year of Age with KMT2A-Rearranged Acute Lymphoblastic Leukemia (ALL); Results from the Children’s Oncology Group (COG) Trial AALL15P1
Authors include John Kairalla, Ph.D.
5:30-7:30 p.m.
2237 Racial, Ethnic and Socioeconomic Disparity in Outcomes of Patients with Chronic Graft-Versus-Host Disease: A CIBMTR Analysis
Presenter: Nosha Farhadfar, M.D., Zeina Al-Mansour, M.D., and John Wingard, M.D.
5:30-7:30 p.m.
1449 Dual BCL-XL/2 Protac 753B Not Only Potently Induces Apoptosis in Venetoclax-Resistant Primary AML Cells but Also Effectively Eliminates Chemotherapy-Induced Senescent AML Cells
Authors include Guangrong Zheng, Ph.D.
5:30-7:30 p.m.
1819 Bortezomib Resistant Multiple Myeloma Shows a Specific Dependency on Ecpas in Vitro and In Vivo
Authors include Amin Sobh, Ph.D.
5:30-7:30 p.m.
1117 Cysteine Sulfenylation of Protein Disulfide Isomerase Links Oxidative Stress to Thrombosis
Authors include Kate Carroll, Ph.D.
5:30-7:30 p.m.
Sunday, Dec. 11
2549 Study of the Dynamics and Diversity of Hematopoietic Stem Cells during Aging and Senolytic Drug Treatment Using Single Cell Transcriptomics
Presenter: Bowen Yan, Ph.D.; Authors include Guangrong Zheng, Ph.D., and Olga Guryanova, M.D., Ph.D.
6-8 p.m.
2646 Genome-Wide CRISPR/Cas9 Screen Identifies AraC-Daunorubicin-Etoposide (ADE) Response Modulators Associated with Clinical Outcomes in Pediatric AML
Presenter: Nam H.K. Nguyen, M.S., PharmD.; Authors include Chris Vulpe, M.D., Ph.D., and Jatinder Lamba, Ph.D.
6-8 p.m.
2759 Entospletinib (ENTO) in Combination with Cytarabine (Ara-C) and Daunorubicin (DNR) in Newly Diagnosed (ND) Adult Patients with NPM1-Mutated and FLT3-ITD Wild-Type Acute Myeloid Leukemia (AML) Is Associated with Good Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial
Authors include Zeina Al-Mansour, M.D.
6-8 p.m.
2760 Updated Results from a Phase 1 Study of APVO436, a Novel Bispecific Anti-CD123 x Anti-CD3 Adaptir™ Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome
Authors include Christopher Cogle, M.D.
6-8 p.m.
2627 Gene Editing and Multi-Omics Reveal Novel Metabolic Vulnerabilities in t(4;14)-Associated Multiple Myeloma
Presenter: Amin Sobh, Ph.D. Authors include: Charlotte Kaestner, B.S., Alberto Riva, Ph.D., Alisha Patel, Greeshma Surapaneni, Janai Poullard, Elena Encinas, Richard Bennett, Ph.D., and Jonathan Licht, M.D.
6-8 p.m.
2800 Genome-Wide Association Study Identifies Variants Associated with Clinical Outcomes in Pediatric Patients with Newly Diagnosed Acute Myeloid Leukemia
Presenter: Richard J. Marrero, Pharm.D.; Authors include Jatinder K. Lamba, Ph.D.
6-8 p.m.
2711 Proteomic Analysis Identifies Epigenetic Modifiers and Potential Negative Regulators of Leukemogenesis KMD6A and SETDB1 to be Induced Post In Vivo Decitabine Exposure in Pediatric AML
Presenter: Jatinder K. Lamba, Ph.D.
6-8 p.m.
3579 Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation for Hodgkin and Non-Hodgkin Lymphoma: Secondary Analysis from Two Multi-Center Randomized Controlled Trials of Hematopoietic Cell Transplant Survivorship Interventions
Authors include John Wingard, M.D.
6-8 p.m.
2490 Long-Term Follow-up of Patients with Congenital Thrombotic Thrombocytopenia Purpura Receiving Plasma-Derived Factor VIII Containing (Koate®)
Authors include Anita Rajasekhar, M.D.
6-8 p.m.
Monday, Dec. 12
3874 Sickle Cell Disease Compromises the Hematopoietic Stem Cells Bone Marrow Niche with Age
Authors include Jason Butler, Ph.D.
6-8 p.m.
3875 Netrin-1 Rejuvenates the Aged Hematopoietic Stem Cell Niche By Restoring the DNA Damage Response
Presenter: Jason Butler, Ph.D.
6-8 p.m.
4693 Early Donor T-Cell Engraftment Is Critical for Immune Tolerance in Reduced Intensity Haploidentical Bone Marrow Transplant with Post-Transplant Cyclophosphamide for Sickle Cell Disease: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC2)
Authors include Biljana Horn, M.D.
6-8 p.m.
4085 A Phase 1b Dose Escalation and Expansion Study of SNDX-5613, Azacitidine (AZA) and Venetoclax (VEN) in Newly Diagnosed, Patients ≥ 60 Years with Untreated NPM1-Mutated/ FLT3-Wild Type AML or KMT2A-Rearranged Acute Myeloid Leukemia (AML)
Authors include Zeina Al-Mansour, M.D.
6-8 p.m.
4488 Targeting C3d in Combination with Daratumumab: a Strategy to Enhance Therapeutic Potential in Multiple Myeloma
Authors include Christoph Rader, Ph.D.
6-8 p.m.
3709 No Specific Factors Associated with Risk of Readmission for Rebound Pain in Children with Sickle Cell Disease and Asthma Treated with Systemic Corticosteroids
Presenter: Reema Kashif, M.D.
6-8 p.m.
